The medical industry has almost always been on the radars of investors and for good reason too, considering the sort of wealth that medical stocks have managed to create over the past decades. Ultimately investors need to be in the know with regard to the latest developments in the industry if they are to make informed decisions and hence, it may be a good idea to take a look at the latest news with regards to medical companies. Here is a look at two medical stocks which have been in the news in recent times.
Therma Bright Inc (THRM.V) (OTC:TBRIF) – The first company that one needs to look into in this context is Therma Bright Inc, which had been in focus earlier on in the week on Thursday. The company provided an update with regards to its application process with the United States Food and Drug Administration for the emergency use authorization for its AcuVid™ COVID-19 Rapid Antigen Saliva Test.
It was noted that the executives and the product development personnel at the company have been in discussions with the representatives of the FDA in recent times in order to clear up certain issues with regard to the application. All the answers and clarification have been provided by the company to the FDA as per the announcement earlier this week. Currently, Therma Bright is waiting for an answer from the FDA with regard to the application. It would be interesting to see if the stock gets any attention from investors in the coming week.
Pressure BioSciences (OTC:PBIO) – Another medical stock that may be worth looking into at this point in time is Pressure BioSciences, which had been in the news this past Wednesday. Appearance on popular podcasts can often be an excellent source of publicity for a company and help it in explaining its business to the larger public.
On Wednesday, the company’s Chief Executive Officer Richard T Schumacher went on The Stock Day Podcast and delivered an interview. During the interview, Schumacher spoke about the various aspects of the company’s business and provided valuable information that could help investors in having a greater idea about the company. It is now going to be interesting to see if the stock does come on to the radars of investors over the course of the coming days.
Immunoprecise Antibodies Ltd (NASDAQ:IPA) (IPA.V) is a full-service contract research organization (CRO) for therapeutic antibody discovery and development. The Company’s technology suite supports the biopharmaceutical industries in their pursuit to discover and develop novel, therapeutic antibodies against various disease targets.
Crystal Research Associates issued a research report on the company. The report states IPA is positioned as a leader in human therapeutic antibody discovery and development, disrupting the conventional multivendor drug discovery model by modernizing the antibody lead candidate selection and downstream development processes.
Med Tech Reporter® shows a list of companies in this stock classification. See More companies now. The Street Med Tech Reporter®
